Department of Radiology, The University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252, USA.
Lancet Oncol. 2013 Jul;14(8):711-20. doi: 10.1016/S1470-2045(13)70216-X. Epub 2013 Jun 7.
The clinical relevance and in-vivo growth rates of small (6-9 mm) colorectal polyps are not well established. We aimed to assess the behaviour of such polyps with CT colonography assessments.
In this longitudinal study, we enrolled asymptomatic adults undergoing routine colorectal cancer screening with CT colonography at two medical centres in the USA. Experienced investigators (PJP, DHK, JLH) measured volumes and maximum linear sizes of polyps in vivo with CT colonography scans at baseline and surveillance follow-up. We defined progression, stability, and regression on the basis of a 20% volumetric change per year from baseline (20% or more growth classed as progression, 20% growth to -20% reduction classed as stable, and -20% or more reduction classed as regression). We compared findings with histological subgroups confirmed after colonoscopy when indicated. This study is registered with ClinicalTrials.gov, number NCT00204867.
Between April, 2004, and June, 2012, we screened 22,006 asymptomatic adults and included 243 adults (mean age 57·4 years [SD 7·1] and median age 56 years [IQR 52-61]; 106 [37%] women), with 306 small colorectal polyps. The mean surveillance interval was 2·3 years (SD 1·4; range 1-7 years; median 2·0 years [IQR 1·1-2·3]). 68 (22%) of 306 polyps progressed, 153 (50%) were stable, and 85 (28%) regressed, including an apparent resolution in 32 (10%) polyps. We established immediate histology in 131 lesions on colonoscopy after final CT colonography. 21 (91%) of 23 proven advanced adenomas progressed, compared with 31 (37%) of 84 proven non-advanced adenomas, and 15 (8%) of 198 other lesions (p<0·0001). The odds ratio for a growing polyp at CT colonography surveillance to become an advanced adenoma was 15·6 (95% CI 7·6-31·7) compared with 6-9 mm polyps detected and removed at initial CT colonography screening (without surveillance). Mean polyp volume change was a 77% increase per year for 23 proven advanced adenomas and a 16% increase per year for 84 proven non-advanced adenomas, but a 13% decrease per year for all proven non-neoplastic or unresected polyps (p<0·0001). An absolute polyp volume of more than 180 mm(3) at surveillance CT colonography identified proven advanced neoplasia (including one delayed cancer) with a sensitivity of 92% (22 of 24 polyps), specificity of 94% (266 of 282 polyps), positive-predictive value of 58% (22 of 38 polyps), and negative-predictive value of 99% (266 of 268 polyps). Only 16 (6%) of the 6-9 mm polyps exceeded 10 mm at follow-up.
Volumetric growth assessment of small colorectal polyps could be a useful biomarker for determination of clinical importance. Advanced adenomas show more rapid growth than non-advanced adenomas, whereas most other small polyps remain stable or regress. Our findings might allow for less invasive surveillance strategies, reserving polypectomy for lesions that show substantial growth. Further research is needed to provide more information regarding the ultimate fate of unresected small polyps without significant growth.
US National Institutes of Health, National Cancer Institute.
直径为 6-9 毫米的结直肠小息肉的临床意义和体内生长速度尚未明确。本研究旨在通过 CT 结肠成像评估此类息肉的生长情况。
这是一项纵向研究,我们纳入了在美国两家医疗中心接受常规结直肠癌筛查的无症状成年人。有经验的研究人员(PJP、DHK、JLH)在基线和随访 CT 结肠成像扫描时测量息肉的体积和最大线性尺寸。我们根据每年体积变化 20%(体积增长 20%以上为进展,20%增长至-20%减少为稳定,-20%或更多减少为消退)来定义进展、稳定和消退。我们将这些发现与结肠镜检查时确认的组织学亚组进行了比较。这项研究在 ClinicalTrials.gov 上注册,编号为 NCT00204867。
2004 年 4 月至 2012 年 6 月期间,我们对 22006 名无症状成年人进行了筛查,并纳入了 243 名成年人(平均年龄 57.4 岁[标准差 7.1],中位年龄 56 岁[IQR 52-61];106 名[37%]女性),共发现 306 个小结直肠息肉。平均随访间隔为 2.3 年(标准差 1.4;范围 1-7 年;中位数 2.0 年[IQR 1.1-2.3])。306 个息肉中,68 个(22%)进展,153 个(50%)稳定,85 个(28%)消退,包括 32 个息肉(10%)明显消失。我们在最后一次 CT 结肠成像后,通过结肠镜对 131 个病变进行了即时组织学检查。23 个证实的高级别腺瘤中,21 个(91%)进展,而 84 个证实的非高级别腺瘤中,只有 31 个(37%)进展,198 个其他病变中,15 个(8%)进展(p<0·0001)。与在初次 CT 结肠成像筛查中检测到并切除(未进行随访)的 6-9 毫米息肉相比,在 CT 结肠成像监测中生长的息肉进展为高级别腺瘤的比值比为 15.6(95%CI 7.6-31.7)。高级别腺瘤的平均每年息肉体积增长率为 77%,而非高级别腺瘤的平均每年息肉体积增长率为 16%,而所有证实的非肿瘤性或未切除息肉的平均每年体积减少率为 13%(p<0·0001)。在 CT 结肠成像监测中,息肉体积超过 180 mm³时,可发现高级别肿瘤(包括一个延迟性癌症),其敏感性为 92%(24 个息肉中的 22 个),特异性为 94%(282 个息肉中的 266 个),阳性预测值为 58%(38 个息肉中的 22 个),阴性预测值为 99%(268 个息肉中的 266 个)。只有 16 个(6%)6-9 毫米的息肉在随访中超过 10 毫米。
直径为 6-9 毫米的结直肠小息肉的体积生长评估可能是确定临床重要性的有用生物标志物。高级别腺瘤的生长速度快于非高级别腺瘤,而大多数其他小息肉保持稳定或消退。我们的研究结果可能允许采用侵袭性更小的监测策略,仅对显示明显生长的病变进行息肉切除术。进一步的研究需要提供更多关于无明显生长的未切除小息肉的最终结局的信息。
美国国立卫生研究院,美国国家癌症研究所。